# Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

> **NCT03167151** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Oxford** · enrollment: 6 (actual)

## Conditions studied

- Non-muscle Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03167151
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-02
- **Primary completion:** 2019-03-26
- **Final completion:** 2019-06-26
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study failed to recruit within the permitted timeframe
- **Last updated:** 2020-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03167151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03167151, "Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03167151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*